Shield Therapeutics plc (LON:STX – Get Free Report)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 7.74 and traded as low as GBX 5.70. Shield Therapeutics shares last traded at GBX 5.75, with a volume of 1,676,021 shares traded.
Shield Therapeutics Price Performance
The company has a debt-to-equity ratio of -199.87, a quick ratio of 2.16 and a current ratio of 0.90. The stock has a market capitalization of £60.90 million, a price-to-earnings ratio of -2.85 and a beta of 1.88. The company has a 50-day moving average of GBX 7.74 and a 200-day moving average of GBX 9.12.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
